Flavien Roux

595 total citations
9 papers, 484 citations indexed

About

Flavien Roux is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Flavien Roux has authored 9 papers receiving a total of 484 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Surgery, 5 papers in Endocrinology, Diabetes and Metabolism and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Flavien Roux's work include Diabetes Treatment and Management (5 papers), Pancreatic function and diabetes (5 papers) and Diabetes Management and Research (3 papers). Flavien Roux is often cited by papers focused on Diabetes Treatment and Management (5 papers), Pancreatic function and diabetes (5 papers) and Diabetes Management and Research (3 papers). Flavien Roux collaborates with scholars based in Germany, France and United States. Flavien Roux's co-authors include Afshin Salsali, Ludwig Merker, Anita Vedel Christiansen, Uli C. Broedl, Gabriel Kim, Péter Stella, Hans J. Woerle, Thomas Meinicke, James S. Douglas and B M Grandordy and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, Cancer Research and The Lancet Oncology.

In The Last Decade

Flavien Roux

9 papers receiving 474 citations

Peers

Flavien Roux

EDM

SURGE

PRM

ONCOL

Mario Maldonado United States

Anne Hickman United States

John Xu United States

Takahiro Kawai Japan

Nobuko Maruyama Japan

Yuichi Terawaki Japan

Ryoko Motonaga Japan

Jinglan Xu Japan

Aditya Goud United States

Mario Maldonado United States

Flavien Roux

320 ×1.0

EDM

115 ×0.6

112 ×0.8

SURGE

66 ×0.5

PRM

51 ×0.5

ONCOL

Citations per year, relative to Flavien Roux Flavien Roux (= 1×) peers Mario Maldonado

Countries citing papers authored by Flavien Roux

Since Specialization

Citations

This map shows the geographic impact of Flavien Roux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Flavien Roux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Flavien Roux more than expected).

Fields of papers citing papers by Flavien Roux

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Flavien Roux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Flavien Roux. The network helps show where Flavien Roux may publish in the future.

Co-authorship network of co-authors of Flavien Roux

This figure shows the co-authorship network connecting the top 25 collaborators of Flavien Roux. A scholar is included among the top collaborators of Flavien Roux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Flavien Roux. Flavien Roux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Bahleda, Rastislav, Antoine Hollebecque, Andréa Varga, et al.. (2015). Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. British Journal of Cancer. 113(10). 1413–1420. 16 indexed citations

Roden, Michael, Ludwig Merker, Anita Vedel Christiansen, et al.. (2015). Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovascular Diabetology. 14(1). 154–154. 101 indexed citations

Kovács, Christopher S., Ludwig Merker, Anita Vedel Christiansen, et al.. (2015). Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics. 37(8). 1773–1788.e1. 91 indexed citations

Haering, Hans-Ulrich, Ludwig Merker, Anita Vedel Christiansen, et al.. (2015). Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Research and Clinical Practice. 110(1). 82–90. 67 indexed citations

Merker, Ludwig, H.-U. Häring, Anita Vedel Christiansen, et al.. (2015). Empagliflozin as add‐on to metformin in people with Type 2 diabetes. Diabetic Medicine. 32(12). 1555–1567. 68 indexed citations

Häring, HU, et al.. (2015). Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes. Diabetologie und Stoffwechsel. 10(S 01). 1 indexed citations

Cortés, Javier, Véronique Dièras, Jungsil Ro, et al.. (2015). Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. The Lancet Oncology. 16(16). 1700–1710. 100 indexed citations

Cortés, Javier, Véronique Dièras, Jungsil Ro, et al.. (2015). Abstract P5-19-07: Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-Breast 3. Cancer Research. 75(9_Supplement). P5–19. 3 indexed citations

Roux, Flavien, B M Grandordy, & James S. Douglas. (1996). Functional and Binding Characteristics of Long-Acting Beta 2-Agonists in Lung and Heart. American Journal of Respiratory and Critical Care Medicine. 153(5). 1489–1495. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact